Video

Does Belantamab Have a Place in Multiple Myeloma Treatment?

Author(s):

Sagar Lonial, MD,Amrita Krishnan, MD

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Related Videos
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Michel Delforge, MD, PhD
Related Content
David R. Oveisi, MD
November 20th 2024

Expanded Indications for CAR T-Cell Therapies Shepard in New Era of Myeloma Care

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Multiple myeloma Image credit: LASZLO – stock.adobe.com
November 15th 2024

Isatuximab Plus VRd Earns CHMP Recommendation for Newly Diagnosed, Transplant-Ineligible Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma
November 8th 2024

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma

FDA
November 6th 2024

FDA Grants Orphan Drug Designation to LBL-034 for Multiple Myeloma